메뉴 건너뛰기




Volumn 5, Issue , 2012, Pages 161-170

Weekly paclitaxel, gemcitabine, and external irradiation followed by randomized farnesyl transferase inhibitor R115777 for locally advanced pancreatic cancer

Author keywords

Gemcitabine; Irradiation; Paclitaxel; Pancreas cancer

Indexed keywords

GEMCITABINE; PACLITAXEL; RI 115777; RI 15777; TRANSFERASE INHIBITOR; UNCLASSIFIED DRUG;

EID: 84868370888     PISSN: 11786930     EISSN: None     Source Type: Journal    
DOI: 10.2147/OTT.S33560     Document Type: Article
Times cited : (17)

References (30)
  • 1
    • 0142121292 scopus 로고    scopus 로고
    • Treatment of locally advanced pancreatic cancer in the real world: Population-based practices and effectiveness
    • Krzyzanowska MK, Weeks JC, Earle CC. Treatment of locally advanced pancreatic cancer in the real world: population-based practices and effectiveness. J Clin Oncol. 2003;21(18):3409-3414.
    • (2003) J Clin Oncol , vol.21 , Issue.18 , pp. 3409-3414
    • Krzyzanowska, M.K.1    Weeks, J.C.2    Earle, C.C.3
  • 2
    • 65549143674 scopus 로고    scopus 로고
    • Chemoradiotherapy in the management of locally advanced pancreatic carcinoma: A qualitative systematic review
    • Huguet F, Girard N, Guerche CS, et al. Chemoradiotherapy in the management of locally advanced pancreatic carcinoma: a qualitative systematic review. J Clin Oncol. 2009;27(13):2269-2277.
    • (2009) J Clin Oncol , vol.27 , Issue.13 , pp. 2269-2277
    • Huguet, F.1    Girard, N.2    Guerche, C.S.3
  • 3
    • 77954771890 scopus 로고    scopus 로고
    • 5FU/leucovorin [LV], irinotecan [I], and oxaliplatin [O] versus gemcitabine [G] as first-line treatment for meta- static pancreatic adenocarcinoma (MPA): Preplanned interim analysis results of the PRODIGE 4/ACCORD 11 trial
    • abstract 4010
    • Conroy T, Desseigne M, Ychou M, et al. Randomized Phase III trial comparing FOLFIRINOX (F: 5FU/leucovorin [LV], irinotecan [I], and oxaliplatin [O] versus gemcitabine [G] as first-line treatment for meta- static pancreatic adenocarcinoma (MPA): preplanned interim analysis results of the PRODIGE 4/ACCORD 11 trial. J Clin Oncol. 2010; 28(Suppl, abstract 4010):S15.
    • (2010) J Clin Oncol , vol.28 , Issue.SUPPL.
    • Conroy, T.1    Desseigne, M.2    Ychou, M.3
  • 4
    • 0035501222 scopus 로고    scopus 로고
    • Radiotherapy and continuous infusion 5-fluorouracil in patients with nonresectable pancreatic carcinoma
    • Bo G, De Paoli A, Innocente R, et al. Radiotherapy and continuous infusion 5-fluorouracil in patients with nonresectable pancreatic carcinoma. Int J Radiat Oncol Biol Phys. 2001;51:736-740.
    • (2001) Int J Radiat Oncol Biol Phys , vol.51 , pp. 736-740
    • Bo, G.1    de Paoli, A.2    Innocente, R.3
  • 5
    • 70249130566 scopus 로고    scopus 로고
    • Phase II study of bevacizumab with concurrent capecitabine and radiation followed by maintenance gemcitabine and bevacizumab for locally advanced pancreatic cancer: Radiation Therapy Oncology Group RTOG 0411
    • Crane CH, Winter K, Regine W, et al. Phase II study of bevacizumab with concurrent capecitabine and radiation followed by maintenance gemcitabine and bevacizumab for locally advanced pancreatic cancer: Radiation Therapy Oncology Group RTOG 0411. J Clin Oncol. 2009;27: 4096-4102.
    • (2009) J Clin Oncol , vol.27 , pp. 4096-4102
    • Crane, C.H.1    Winter, K.2    Regine, W.3
  • 6
    • 0036643954 scopus 로고    scopus 로고
    • A single-institution experience with concurrent capecitabine and radiation therapy in gastrointestinal malignancies
    • Vaishampayan UN, Ben-Josef E, Philip PA, et al. A single-institution experience with concurrent capecitabine and radiation therapy in gastrointestinal malignancies. Int J Radiat Oncol Biol Phys. 2002;53: 675-679.
    • (2002) Int J Radiat Oncol Biol Phys , vol.53 , pp. 675-679
    • Vaishampayan, U.N.1    Ben-Josef, E.2    Philip, P.A.3
  • 7
    • 0027160447 scopus 로고
    • Investigation of taxol as a potential radiation sensitizer
    • Choy H, Rodriguez F F, Koester S, et al. Investigation of taxol as a potential radiation sensitizer. Cancer. 1993;71:3774-3778.
    • (1993) Cancer , vol.71 , pp. 3774-3778
    • Choy, H.1    Rodriguez, F.F.2    Koester, S.3
  • 8
    • 0035312196 scopus 로고    scopus 로고
    • Paclitaxel and concurrent radiation for locally advanced pancreatic cancer
    • Safran H, Moore T, Iannitti D, et al. Paclitaxel and concurrent radiation for locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys. 2001;49:1275-1279.
    • (2001) Int J Radiat Oncol Biol Phys , vol.49 , pp. 1275-1279
    • Safran, H.1    Moore, T.2    Iannitti, D.3
  • 9
    • 0031044606 scopus 로고    scopus 로고
    • Paclitaxel and concurrent radiation for locally advanced pancreatic and gastric cancer: A Phase I study
    • Safran H, King T P, Choy H, et al. Paclitaxel and concurrent radiation for locally advanced pancreatic and gastric cancer: a Phase I study. J Clin Oncol. 1997;15:901-907.
    • (1997) J Clin Oncol , vol.15 , pp. 901-907
    • Safran, H.1    King, T.P.2    Choy, H.3
  • 10
    • 0842327290 scopus 로고    scopus 로고
    • A Phase II study of external beam irradiation and weekly paclitaxel for non-metastatic, unresectable pancreatic cancer: RTOG 98-12
    • Rich TA, Harris J, Abrams R, et al. A Phase II study of external beam irradiation and weekly paclitaxel for non-metastatic, unresectable pancreatic cancer: RTOG 98-12. Am J Clin Oncol. 2007;27(1): 51-56.
    • (2007) Am J Clin Oncol , vol.27 , Issue.1 , pp. 51-56
    • Rich, T.A.1    Harris, J.2    Abrams, R.3
  • 11
    • 8244254377 scopus 로고    scopus 로고
    • Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial
    • Burris HA, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997;15:2403-2413.
    • (1997) J Clin Oncol , vol.15 , pp. 2403-2413
    • Burris, H.A.1    Moore, M.J.2    Andersen, J.3
  • 12
    • 0035577889 scopus 로고    scopus 로고
    • Phase I study of twice-weekly gemcitabine and concurrent thoracic radiation for patients with locally advanced non-small-cell lung cancer
    • Blackstock AW, Lesser GJ, Fletcher-Steede J, et al. Phase I study of twice-weekly gemcitabine and concurrent thoracic radiation for patients with locally advanced non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2001;51:1281-1289.
    • (2001) Int J Radiat Oncol Biol Phys , vol.51 , pp. 1281-1289
    • Blackstock, A.W.1    Lesser, G.J.2    Fletcher-Steede, J.3
  • 13
    • 0000643645 scopus 로고    scopus 로고
    • A Phase I study of preoperative gemcitabine (GEM) with radiation therapy (RT) followed by postoperative GEM for patients with localized, resectable pancreatic adenocarcinoma (PAC)
    • Hoffman J P, McGinn CJ, Szarka C, et al. A Phase I study of preoperative gemcitabine (GEM) with radiation therapy (RT) followed by postoperative GEM for patients with localized, resectable pancreatic adenocarcinoma (PAC). Proc Am Soc Clin Oncol. 2007;18:283a.
    • (2007) Proc Am Soc Clin Oncol , vol.18
    • Hoffman, J.P.1    McGinn, C.J.2    Szarka, C.3
  • 14
    • 0036719234 scopus 로고    scopus 로고
    • Gemcitabine, paclitaxel, and radiation for locally advanced pancreatic cancer: A Phase I trial
    • Safran H, Dipetrillo T, Iannitti D, et al. Gemcitabine, paclitaxel, and radiation for locally advanced pancreatic cancer: a Phase I trial. Int J Radiat Oncol Biol Phys. 2002;54:137-141.
    • (2002) Int J Radiat Oncol Biol Phys , vol.54 , pp. 137-141
    • Safran, H.1    Dipetrillo, T.2    Iannitti, D.3
  • 15
    • 43249110658 scopus 로고    scopus 로고
    • Determinants of RASistance to anti-epidermal growth factor receptor agents
    • Baselga J, Rosen N. Determinants of RASistance to anti-epidermal growth factor receptor agents. J Clin Oncol. 2008;26:1582-1584.
    • (2008) J Clin Oncol , vol.26 , pp. 1582-1584
    • Baselga, J.1    Rosen, N.2
  • 16
    • 0032704708 scopus 로고    scopus 로고
    • Ras protein farnesyltransferase: A strategic target for anticancer therapeutic development
    • Rowinsky EK, Windle JJ, Von Hoff DD. Ras protein farnesyltransferase: a strategic target for anticancer therapeutic development. J Clin Oncol. 1999;17:3631-3652.
    • (1999) J Clin Oncol , vol.17 , pp. 3631-3652
    • Rowinsky, E.K.1    Windle, J.J.2    Von Hoff, D.D.3
  • 17
    • 0024202761 scopus 로고
    • Sample size considerations for studies comparing survival curves using historical controls
    • Dixon DO, Simon R. Sample size considerations for studies comparing survival curves using historical controls. J Clin Epidemiol. 1988;41:1209-1213.
    • (1988) J Clin Epidemiol , vol.41 , pp. 1209-1213
    • Dixon, D.O.1    Simon, R.2
  • 18
    • 33845382806 scopus 로고    scopus 로고
    • Non-parametric estimation from incomplete observation
    • Kaplan EL, Meier P. Non-parametric estimation from incomplete observation. J Am Stat. 2007;53:457-481.
    • (2007) J Am Stat , vol.53 , pp. 457-481
    • Kaplan, E.L.1    Meier, P.2
  • 19
    • 0000336139 scopus 로고    scopus 로고
    • Regression models and life tables
    • Cox DR. Regression models and life tables. J R Stat Soc. 2007;34: 187-229.
    • (2007) J R Stat Soc , vol.34 , pp. 187-229
    • Cox, D.R.1
  • 20
    • 0037783798 scopus 로고    scopus 로고
    • Clinical research in pancreatic cancer: The Radiation Therapy Oncology Group trials
    • Willett CG, Safran H, Abrams RA, et al. Clinical research in pancreatic cancer: the Radiation Therapy Oncology Group trials. Int J Radiat Oncol Biol Phys. 2003;56:31-37.
    • (2003) Int J Radiat Oncol Biol Phys , vol.56 , pp. 31-37
    • Willett, C.G.1    Safran, H.2    Abrams, R.A.3
  • 21
    • 0030748489 scopus 로고    scopus 로고
    • Enhanced radioresponse of paclitaxel sensitive and -resistant tumours in vivo
    • Milross CG, Mason KA, Hunter NR, et al. Enhanced radioresponse of paclitaxel sensitive and -resistant tumours in vivo. Eur J Cancer. 1997;33:1299-1308.
    • (1997) Eur J Cancer , vol.33 , pp. 1299-1308
    • Milross, C.G.1    Mason, K.A.2    Hunter, N.R.3
  • 22
    • 0029113685 scopus 로고
    • Effect of paclitaxel (taxol) alone and in combination with radiation on the gastrointestinal mucosa
    • Mason KA, Milas L, Peters LJ. Effect of paclitaxel (taxol) alone and in combination with radiation on the gastrointestinal mucosa. Int J Radiat Oncol Biol Phys. 1995;32:1381-1389.
    • (1995) Int J Radiat Oncol Biol Phys , vol.32 , pp. 1381-1389
    • Mason, K.A.1    Milas, L.2    Peters, L.J.3
  • 23
    • 9544220646 scopus 로고    scopus 로고
    • p53 mutations do not predict response to paclitaxel/radiation for nonsmall cell lung carcinoma
    • Safran H, King T, Choy H, et al. p53 mutations do not predict response to paclitaxel/radiation for nonsmall cell lung carcinoma. Cancer. 1996;78:1203-1210.
    • (1996) Cancer , vol.78 , pp. 1203-1210
    • Safran, H.1    King, T.2    Choy, H.3    Et al.4
  • 24
    • 0002291979 scopus 로고    scopus 로고
    • Gemcitabine as a radiation sensitizer
    • Lawrence T. Gemcitabine as a radiation sensitizer. Semin Oncol. 2007;22:68-71.
    • (2007) Semin Oncol , vol.22 , pp. 68-71
    • Lawrence, T.1
  • 25
    • 4644239753 scopus 로고    scopus 로고
    • Cancer and Leukemia Group B (CALGB) 89805: Phase II chemoradiation trial using gemcitabine in patients with locoregional adenocarcinoma of the pancreas
    • Blackstock AW, Tepper JE, Niedwiecki D, et al. Cancer and Leukemia Group B (CALGB) 89805: Phase II chemoradiation trial using gemcitabine in patients with locoregional adenocarcinoma of the pancreas. Int J Gastrointest Cancer. 2003;34:107-116.
    • (2003) Int J Gastrointest Cancer , vol.34 , pp. 107-116
    • Blackstock, A.W.1    Tepper, J.E.2    Niedwiecki, D.3
  • 26
    • 0035890443 scopus 로고    scopus 로고
    • Phase I trial of radiation dose escalation with concurrent weekly full-dose gemcitabine in patients with advanced pancreatic cancer
    • McGinn CJ, Zalupski MM, Shureiqi I, et al. Phase I trial of radiation dose escalation with concurrent weekly full-dose gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol. 2001;19:4202-4208.
    • (2001) J Clin Oncol , vol.19 , pp. 4202-4208
    • McGinn, C.J.1    Zalupski, M.M.2    Shureiqi, I.3
  • 27
    • 0028603395 scopus 로고
    • Protein farnesyltransferase inhibitors block the growth of ras-dependent tumors in nude mice
    • Kohl NE, Wilson FR, Mosser SD, et al. Protein farnesyltransferase inhibitors block the growth of ras-dependent tumors in nude mice. Proc Natl Acad Sci U S A. 1994;91:9141-9145.
    • (1994) Proc Natl Acad Sci U S A , vol.91 , pp. 9141-9145
    • Kohl, N.E.1    Wilson, F.R.2    Mosser, S.D.3
  • 28
    • 23844517889 scopus 로고    scopus 로고
    • A Phase II study of farnesyl transferase inhibitor R115777 in pancreatic cancer: A Southwest oncology group (SWOG 9924) study
    • Macdonald JS, McCoy S, Whitehead R P, et al. A Phase II study of farnesyl transferase inhibitor R115777 in pancreatic cancer: a Southwest oncology group (SWOG 9924) study. Invest New Drugs. 2005;23:485-487.
    • (2005) Invest New Drugs , vol.23 , pp. 485-487
    • Macdonald, J.S.1    McCoy, S.2    Whitehead, R.P.3
  • 30
    • 2342645506 scopus 로고    scopus 로고
    • Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer
    • Van Cutsem E, de Belde H V, Karasek P, et al. Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer. J Clin Oncol. 2004;22:1430-1438.
    • (2004) J Clin Oncol , vol.22 , pp. 1430-1438
    • van Cutsem, E.1    de Belde, H.V.2    Karasek, P.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.